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O B J E C T I V E S This study sought to determine whether novel markers not involving ionizing
radiation could predict coronary artery calcium (CAC) progression in a low-risk population.
B A C KG ROUND Increase in CAC scores over time (CAC progression) improves prediction of
coronary heart disease (CHD) events. Due to radiation exposure, CAC measurement represents an
undesirable method for repeated risk assessment, particularly in individuals with low predicted risk
(Framingham Risk Score [FRS] 10%).
METHOD S From 6,814 participants in MESA (Multi-Ethnic Study of Atherosclerosis), 2,620 individ-
uals were classiﬁed as low risk for CHD events (FRS 10%) and had follow-up CAC measurement. In
addition to traditional risk factors (RFs), various combinations of novel marker models were selected on
the basis of data-driven, clinical, or backward stepwise selection techniques.
R E S U L T S Mean follow-up was 2.5 years. CAC progression occurred in 574 participants (22% overall;
214 of 1,830 with baseline CAC  0 and 360 of 790 with baseline CAC 0). Addition of various
combinations of novel markers to the base model (c statistic  0.711) revealed improvements in
discrimination of approximately only 0.005 each (c statistics 0.7158, 0.7160, and 0.7164) for the best-ﬁt
models. All 3 best-ﬁt novel marker models calibrated well but were similar to the base model in predicting
individual risk probabilities for CAC progression. The highest prevalence of CAC progression occurred in the
highest compared with the lowest probability quartile groups (39.2% to 40.3% vs. 6.4% to 7.1%).
CONC L U S I O N S In individuals at low predicted risk according to FRS, traditional risk factors
predicted CAC progression in the short term with good discrimination and calibration. Prediction
improved minimally when various novel markers were added to the model. (J Am Coll Cardiol Img
2012;5:144–53) © 2012 by the American College of Cardiology Foundation
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he Framingham Risk Score (FRS) has
been validated as a useful tool in the estima-
tion of 10-year risk of coronary heart disease
(CHD) (1). However, events may still occur
mong those predicted to be at low (10%) 10-year
HD risk (2–4) and could amount to a significant
umber given the large size of this group (75% of
he population) (5–7). As such, identification of
actors associated with CHD events in low-risk
ersons is imperative. Because of limitations of the
RS for risk prediction in individuals, much effort
as been targeted toward improving identification
f persons at risk for coronary events.
The coronary artery calcium (CAC) Agatston
core predicts coronary events beyond the FRS risk
actors (3,4,8) and is predictive of coronary events
ven in individuals with low FRS (2,9). Some
xpert panels recommend some CAC screening in
ersons at lower risk for CHD events (10,11).
owever, due to ionizing radiation exposure as well
s associated cancer risks and costs, computed
omography (CT) scanning likely represents an
ndesirable method of repeated screening for
HD, particularly among persons at low risk. This
act therefore underscores the need for alternative
ethods of risk assessment, not involving radiation
n this population. To this effect, a recent cross-
ectional study by our group (12) demonstrated that
n individuals at low risk according to FRS, a model
ontaining traditional cardiovascular risk factors
ad excellent discrimination for CAC 300. This
odel was only modestly improved with the addition of
ovel markers (individually or in combination).
Studies have linked CAC progression to coro-
ary events, increased all-cause mortality, and an
nfavorable prognosis (13–16) and have even sug-
ested CAC progression to be a better predictor of
VD risk than baseline CAC score (17). Serial
ssessment of CAC scores has been proposed for
onitoring progression of atherosclerosis and for
ssessing the effectiveness of medical therapies
imed at reducing cardiac risk (17). Although base-
ine CAC score likely reflects previous coronary
therosclerotic plaque burden, CAC progression
robably provides insight into ongoing current dis-
ase activity. Although past studies suggest that the
ost consistent predictors of CAC progression
regardless of risk level) are age and initial CAC
urden (18–21), other factors (including novel risk
arkers) associated with CAC progression have not
een routinely examined. Identification of factors
nvolved in atherosclerosis development and pro-
ression could help identify factors that can beodified, prevented, or both, and may be useful to
dentify those among the lower predicted-risk strata
ho actually will experience events.
The objective of this study was to identify novel
arkers or traditional cardiovascular risk factors
hat are associated with CAC progression (incident
r increased CAC scores) among low-risk partici-
ants (FRS10%) who, due to the large size of the
roup, make up a significant proportion of CHD/
VD events observed in the general population.
M E T H O D S
MESA (Multi-Ethnic Study of Atherosclerosis) is
a prospective cohort study examining measures of
subclinical atherosclerosis, progression of subclini-
cal atherosclerosis, and conversion to clinical events.
Details of the study design, as well as
inclusion/exclusion criteria and baseline
characteristics, have been described previ-
ously (8). Briefly, at baseline the cohort
included 6,814 participants (3,213 men
and 3,601 women) aged 45 to 84 years
from 4 different racial/ethnic groups (38%
white, 28% African American, 22% His-
panic, and 12% Chinese) in 6 U.S. com-
munities (Baltimore, Maryland; Chicago,
Illinois; Forsyth County, North Carolina;
Los Angeles, California; New York, New
York; and St. Paul, Minnesota). The par-
ticipants were free of clinical cardiovascu-
lar disease at first examination (July 2000
to August 2002). The institutional review
boards at all participating centers ap-
proved the study, and all participants gave
informed consent. The study was powered
to detect relationships between risk factors
with a prevalence of 10% in the cohort, and the
resence of coronary calcium with an odds ratio
f 1.5.
For the current study, we included men and
omen aged 79 years at baseline, categorized as
eing at low 10-year risk for CHD events (FRS
10%) (1). The present analyses excluded partici-
ants with coronary risk equivalents (non-low risk)
ccording to National Cholesterol Education Pro-
ram–Adult Treatment Panel III definitions, in-
luding a diagnosis of diabetes, peripheral arterial
isease (ankle-brachial index 0.9), carotid artery
isease (50% carotid artery stenosis), history of
bdominal aortic aneurysm, severe kidney disease
glomerular filtration rate 30 ml/min/1.73 m2
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146[22] equation). Other exclusion criteria are detailed
in Figure 1.
Baseline examination, laboratory data, cardiac
CT, and carotid ultrasonography ascertainment
have been described elsewhere (8,23). Carotid ul-
trasound was performed using high-resolution
B-mode ultrasound. We used the common carotid
artery measurements in our data analysis. CAC was
measured at baseline MESA examination 1 (2000
to 2002) for all participants. Follow-up CAC mea-
surements were performed on one-half of the co-
hort (randomly selected) at the second examination
(2002 to 2004) and the other half at the third
examination (2004 to 2005) at an average of 1.7 and
3.3 years after the baseline examination, respec-
tively. FRS was calculated using age, total and
high-density lipoprotein (HDL) cholesterol levels,
current smoking status, systolic blood pressure
(SBP), and the use of antihypertensive medication
using the risk prediction functions from the Na-
tional Cholesterol Education Program–Adult
Treatment Panel III guidelines (24).
Deﬁnitions. Body mass index (BMI) was defined as
eight in kilograms divided by height in meters
quared. Medication use was derived from medica-
ion lists and clinical staff entry of prescribed med-
cations. Aspirin use was defined as 3 days per
eek at baseline. Physical activity was measured
sing a semiquantitative questionnaire adapted
rom the Cross-Cultural Activity Participation
tudy (25).
low Diagram
ria for the study analysis are detailed in this ﬂow diagram. CAC 
lcium; FRS  Framingham Risk Score; MESA  Multi-Ethnic Study
NCEP-ATP III  National Cholesterol Education Program–Adultd
I.Because there is no agreed on definition for CAC
rogression in the literature, we used the CAC
rogression definition described by Berry et al. in a
revious MESA study (26): among those with
AC  0 at baseline, CAC progression or “inci-
ent CAC” was defined as CAC 0 at follow-up.
or those with presence of any CAC at baseline,
AC progression or “increased CAC” was defined
s either an annualized change of 10 Agatston units
t follow-up among participants with 0  CAC 
100 at baseline; or an annualized percentage change
(annualized change in CAC score divided by the
baseline CAC score) 10% among participants
with CAC 100 at baseline. This method allows
for a categorical definition of CAC progression
(progression versus no progression).
Statistical analysis. All analyses were performed us-
ng SAS software, version 9.2 (SAS Institute, Cary,
orth Carolina). A 2-tailed value of p  0.05 was
onsidered statistically significant. Baseline charac-
eristics were compared according to CAC progres-
ion status using general linear models for contin-
ous variables and cross-tabulations for categorical
ariables. Biomarkers and one subclinical measure
f vascular disease (novel markers) were evaluated
nd include low-density lipoprotein particle num-
er (LDLpn), urine albumin, C-reactive protein
CRP) using a high-sensitivity assay, D-dimer,
actor VIIIc, total homocysteine, fibrinogen, cysta-
in C, soluble intercellular adhesion molecule
sICAM)-1, and carotid intima-media thickness
CIMT). sICAM had values missing at random,
hich were filled in using multiple imputation
echniques in secondary analyses (27). Logistic
egression was used to obtain odds ratios per 1
D higher baseline value of individual novel
arkers. This analysis was conducted with CAC
rogression overall, and with incident and in-
reased CAC separately. The first model adjusted
or age only; the second model adjusted for
raditional cardiovascular risk factors including
ge, sex, race/ethnicity, SBP, diastolic blood
ressure, hypertension treatment, total and HDL
holesterol, current smoking, BMI, physical ac-
ivity, and family history of heart attack (base
odel for remainder of analyses).
Novel markers were added individually to the
ase model to assess their independent associations
ith CAC presence. Using this approach, various
odels were fitted to estimate the associations of
ombinations of novel markers with CAC progres-
ion (incident plus increased CAC) using data-Figure 1. Study F
The exclusion crite
coronary artery ca
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147cantly associated with CAC in multivariable
analysis from this and our prior study [12]), mech-
anistic approaches/clinically available covariates
(combination of measures from each major biologic/
pathophysiological group), and backward stepwise
selection statistical techniques. Thus, the base
model made up of traditional risk factors was
combined with several novel marker combinations
to create the best-fit models: fibrinogen, sICAM,
factor VIIIc, CIMT (model 1); LDLpn, CRP,
fibrinogen, urine albumin, sICAM (model 2); and
an unbiased statistical approach using a backward
stepwise selection model including all potential
variables, with p  0.10 selected for model reten-
tion (model 3). Incident CAC and increased CAC
were also assessed separately.
P values obtained using likelihood ratio tests
were used to determine the level of significance of
each model relative to the base model; Akaike
information criterion (AIC) assessed the level of
informativeness of each model, with lower values
indicating greater informativeness; and the c
statistic measured the discriminative power of
each model, with higher values indicating better
fit. Receiver-operating characteristic curves were
then plotted for the base model, as well as the combi-
nation models exhibiting the greatest levels of discrimi-
nation for advanced CAC (best-fit models).
R E S U L T S
Baseline characteristics. Among 6,814 MESA par-
icipants, 2,620 aged 79 years were classified as
ow 10-year FRS CHD risk and had follow-up CT
cans (overall mean age 56.9  8.7 years; women
8.6  9.0 years; men 52.5  6.1 years). Overall
ean follow-up between CAC measurements was
.5 years. Among 1,830 participants with baseline
AC  0, a total of 214 (11.7%) developed CAC
incident CAC), whereas among 790 participants
ith baseline CAC 0, a total of 360 (45.6%) had
ncreased CAC. The 478 participants who were
xcluded because of missing novel marker and
ollow-up CAC measurements had higher SBP,
MI, and triglyceride levels and included more
mokers, but they had similar baseline FRS and
AC scores when compared with those without
issing data.
Almost all of the lifestyle and traditional risk factors
ere associated with CAC progression univariately
xcept race/ethnicity, sex, HDL cholesterol, current
moking, and physical activity (Table 1). Baseline FRS,
AC score, and absence of CAC were significantlyssociated with CAC progression. Higher mean
alues of all the novel markers were significantly
ssociated with CAC progression (Table 2).
Table 1. Baseline Characteristics and CAC Progression Among L
No CAC Progression
(n  2,046)
CAC Pr
(n 
Age (yrs) 55.9 8.3 60.4
Female 72.5 7
Race/ethnicity
White 39.3 4
Black 26.1 2
Chinese 13.3 1
Hispanic 21.3 1
SBP (mm Hg) 118.2 18.3 124.9
DBP (mm Hg) 69.9 10.0 71.4
BMI (kg/m2) 27.7 5.5 28.8
Total cholesterol (mg/dl) 195.3 33.1 200.7
HDL (mg/dl) 55.4 15.4 54.1
LDL (mg/dl) 117.1 29.8 120.5
Triglycerides (mg/dl) 114.3 63.6 127.3
Current smoking 9.04 1
HTN treatment 17.3 3
Family history of CHD 35.8 4
Mean baseline FRS (%) 3.0 2.5 4.1
Mean baseline CAC score
(in CAC 0)
23.0 178.0 106.8
Median baseline CAC score
(in CAC 0)
18.7 8
CAC  0 79.0 3
Education
Less than high school 12.5 1
High school 16.2 1
College or bachelor 50.1 5
Graduate school or professional 21.2 1
Physical activity* 924.7 2,608.7 1,000.0
Marital status (married) 62.4 5
Income ($)
25,000 23.0 2
25,000–50,000 28.5 3
50,000–75,000 20.0 1
75,000 28.5 2
Health insurance 89.6 9
Medications use
Aspirin 10.6 1
ACEI/ARB use 7.5 1
Beta-blocker 4.7
Nitrates 0.05
Calcium blocker 6.0 1
Estrogen use (women) 30.0 3
Values are mean  SD or %. *Physical activity is deﬁned as vigorous phy
[min]/week, Monday through Sunday).
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin recepto
mass index; CAC  coronary artery calcium; CHD  coronary heart disease;
pressure; FRC  Framingham Risk Score; HDL  high-density lipoprotein; HTNow-Risk Participants
ogression
574) p Value
 9.2 0.01
4.4 0.38
0.08
5.1
4.7
1.9
8.3
 19.2 0.01
 10.1 0.01
 6.2 0.01
 38.0 0.01
 14.8 0.07
 32.0 0.02
 67.8 0.01
0.45 0.31
1.0 0.01
8.4 0.01
 2.5 0.01
 228.8 0.01
0.7 0.01
7.3 0.01
0.03
5.8
7.4
0.2
6.6
 2879.1 0.55
3.7 0.01
0.01
9.6
1.6
5.0
3.8
1.5 0.01
4.4 0.01
3.8 0.01
6.3 0.14
0.17 0.34
0.8 0.01
0.3 0.91
sical activity total (MET
r blocker; BMI  body
DBP  diastolic blood
 hypertension; LDL low-density lipoprotein; MET  metabolic equivalent; SBP  systolic blood pressure.
total homocysteine.
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148Univariate and multivariable models for CAC progres-
sion relative to novel markers. Table 3 displays un-
adjusted and adjusted odds ratios for associations of
baseline individual novel markers with CAC pro-
gression. There was a significant positive associa-
tion of most of the individual novel markers with
CAC progression in the univariate and age-
adjusted models, which were no longer significant
after adjustment for traditional risk factors. When
incident CAC and increased CAC were examined
separately, only CRP was associated with increased
CAC, whereas LDLpn, fibrinogen, cystatin C,
sICAM, and CIMT were associated with incident
CAC after adjusting for age. There were no sex or
race interactions found in any of the models.
Combination novel markers in the prediction of CAC
progression. Selected novel marker combinations
were chosen on the basis of data-driven methods,
clinical/mechanistic approaches, and backward
stepwise selection processes and assessed for their
ability to predict CAC progression. Models with
the best informativeness and discrimination for
CAC progression are displayed in Table 4. Model 1
was the best-fit model from previous data from our
group (12), model 2 was the best-fit model for
clinical/mechanistic relevance, and model 3 reflects
the statistical backward selection process for CAC
progression (incident and increased CAC com-
bined). The base model, composed of traditional
risk factors, discriminated incident CAC better
than increased CAC (c statistic  0.688 vs. 0.645,
respectively). For overall CAC progression, the c
statistic for the base model was 0.711 (AIC 
2,524.65). All 3 best-fit models showed little or no
vel Marker Levels and CAC Progression
Mean Novel Marker Levels
No CAC Progression
(n  2,046)
CAC Progression
(n  574) p Value
1,257.0 352.3 1,307.6 382.7 0.01
/dl) 0.9 2.76 1.6 11.0 0.01
3.6 5.1 4.5 6.7 0.01
0.29 0.56 0.36 0.62 0.01
93 34 99 37 0.01
8.4 3.6 8.9 3.1 0.01
) 335 70 349 71 0.01
0.82 0.15 0.87 0.16 0.01
0.79 0.16 0.84 0.16 0.01
263 74 281 76 0.01
D. *n for sICAM-1  962 without CAC progression, 256 with CAC progression.
itivity C-reactive protein; CIMT  carotid intima-media thickness; LDLpn 
in particle number; sICAM  soluble intercellular adhesion molecule, tHcy Table 2. Mean No
LDLpn (nmol/l)
Urine albumin (mg
hs-CRP (mg/l)
D-dimer (g/ml)
Factor VIIIc (%)
tHcy (mol/l)
Fibrinogen (mg/dl
Cystatin C (mg/l)
C-IMT (mm)
sICAM-1 (ng/ml)*
Values are mean  S
hs-CRP  high-sens
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149ness) over the base model. Nevertheless, model 1
showed the best discrimination (c statistic 
0.7164; AIC  2,518.03), model 3 exhibited the
greatest informativeness (c statistic  0.7158; AIC 
2,513.01), and model 2 had both characteristics
(c statistic 0.7160; AIC 2,517.55, respectively)
(all p  0.01). Accordingly, the ROC curves for
hese 4 models overlapped substantially (Fig. 2).
The predictive utility of the models were further
ssessed by comparing 3 best-fit combination mod-
ls with the base model for their applicability in the
rediction of an individual’s risk for CAC progres-
ion. This analysis was done by first dividing this
ow-risk cohort into quartiles of CAC progression.
he first quartile included participants with lowest
AC progression, whereas the fourth quartile rep-
esented those with highest CAC progression. We
hen estimated the probabilities of CAC progres-
ion using each of our models and divided these
nto quartiles also, going from the lowest (in the
rst quartile) to highest probability (in the fourth
uartile). In so doing, we compared observed CAC
rogression in the study population with the esti-
ated probabilities of CAC progression using each
f our models (Fig. 3). For all 4 models, participants
ith the highest estimated probabilities (the 4th
uartile groups) had very high prevalence of CAC
rogression compared with the lowest quartile
roups (39.2% to 40.3% vs. 6.4% to 7.1%). In
ddition, most of the participants with CAC pro-
ression were from the highest probability quartile
roups. The model-estimated probabilities for the 3
est-fit models were similar to those for the base
odel.
For individual measures, sICAM improved the
statistic of the base model by 0.004 (p  0.01);
RP did not show any improvement over the
ase model (p  0.15). However, baseline CAC
core (for those with CAC 0 at baseline)
mproved the base model c statistic by 0.028 (c
tatistic  0.739). It is noteworthy that in these
ow-risk participants, age (chi-square  107) was
he primary risk factor that drove the fit and
nformativeness of the base model (data not
hown). Other risk factors worth noting included
se of antihypertensive medications (chi-square 
0), HDL cholesterol (chi-square 18), and family
istory of heart attack (chi-square  14).
When we used a more restrictive definition (as
roposed by Chung et al. [28]) for CAC progres-
ion among those with CAC 0 at baseline, we
ound similar results: traditional risk factors re-
ained associated with CAC progression, and ahere was minimal improvement with addition of
ovel markers to the base model. Thirteen inter-
urrent events occurred between baseline and
ollow-up CT scanning for CAC measurement.
here was no change in model output results when
ata were reanalyzed with the exclusion of intercur-
ent events.
D I S C U S S I O N
Major study ﬁndings. In low-risk persons with FRS
10%, novel markers minimally improved the
rediction of CAC progression beyond tradi-
ional cardiovascular risk factors. Individual novel
arker levels were higher and were significantly
Table 4. Novel Marker Combinations Used to Predict CAC Progr
Combination Novel Marker Model
OR per 1 SD
(95% CI) c Statistic
Base model* 0.7110
Model 1 0.7164
Fibrinogen 1.06 (1.05–1.07)
sICAM 1.11 (0.81–1.52)
Factor VIIIc 1.05 (0.89–1.25)
CIMT 1.06 (1.02–1.10)
Model 2 0.7160
LDLpn 0.91 (0.76–1.08)
CRP 1.06 (0.96–1.18)
Fibrinogen 0.98 (0.87–1.11)
Urine albumin 1.11 (0.95–1.31)
sICAM 1.17 (0.96–1.43)
Model 3 (backward stepwise
selection)
0.7158
sICAM 1.18 (0.97–1.43)
Factor VIIIc 1.09 (0.99–1.20)
Age 1.08 (1.06–1.09)
Sex 1.53 (1.17–2.00)
Race/ethnicity 0.87 (0.80–0.95)
DBP 1.02 (1.01–1.03)
Antihypertensive medication use 1.76 (1.39–2.23)
Total cholesterol 1.01 (1.00–1.01)
HDL 0.99 (0.98–0.99)
Smoking 1.42 (0.98–2.06)
BMI 1.03 (1.01–1.05)
Physical activity 1.00 (1.00–1.00)
Family history of heart attack 1.45 (1.19–1.78)
sICAM 1.17 (0.96–1.43) 0.7150
CRP alone 1.07 (0.97–1.18) 0.711
Ln baseline CAC score (for those with
baseline CAC 0, n 790)
1.59 (1.43–1.77) 0.739
*Base model includes age, sex, race/ethnicity, SBP, DBP, antihypertensive m
smoking, total and HDL cholesterol, family history of heart attack, BMI, and phys
models are adjusted for the base model.
AIC  Akaike information criterion; CI  conﬁdence interval; Ln  natural lo
other abbreviations as in Tables 1, 2, and 3.ession
AIC
LR Test
p Value
2,524.65
2,518.03 0.01
2,517.55 0.01
2,513.01
2,515.21 0.01
2,524.66 0.15
edication use, current
ical activity. †The rest of
g; LR  likelihood ratio;ssociated with CAC progression in univariate
risk factor
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150models. However, these associations became
nonsignificant in multivariable models adjusting
for age and other traditional risk factors in these
already low-risk participants. Likewise, the novel
marker combinations that significantly predicted
CAC progression based on likelihood ratio tests
very modestly improved the discrimination of the
base model composed of traditional risk factors.
Furthermore, although these best-fit models cal-
ibrated reasonably well, they were comparable to
the base model in the prediction of an individual’s
risk of CAC progression. Findings were similar
when incident CAC and increased CAC were
examined separately.
Clinical implications. In this study of individuals
classified as being at low 10-year risk for CHD
events, 22% had CAC progression. Among those
with CAC progression, 12% had incident CAC
and 46% had increased CAC over a mean period
of 2.5 years. Because CAC progression has been
linked to CHD events (14 –16), this finding
represents a segment of the low-risk population
at risk for CHD events over a short period of
time who therefore may merit more intensive
Area Under the ROC Curves
ares the receiver-operating characteristic (ROC) curves for the
el with the best-ﬁt models in the prediction of coronary artery
rogression using combination novel markers. Base model: tradi-
factors (age, sex, race/ethnicity, systolic and diastolic blood
hypertension treatment, total and high-density lipoprotein cho-
rrent smoking, body mass index, physical activity, and family
heart attack). Model 1: base model plus ﬁbrinogen, soluble in-
adhesion molecule-1 (sICAM), factor VIIIc, and carotid intima-
kness (CIMT). Model 2: base model plus low-density lipopro-
le number (LDLpn), C-reactive protein, ﬁbrinogen, urine
nd sICAM. Model 3: backward stepwise selection (traditional
s plus sICAM and factor VIIIc).prevention efforts.The findings of our study suggest that tradi-
tional risk factors still play a significant role in
predicting disease progression, regardless of low-
risk status. These findings are concordant with a
previous cross-sectional study from our group
(12), which showed that, even in people predicted
to be at low risk for CHD events, traditional risk
factors were still significantly associated with
presence of any CAC and CAC 300. Tradi-
tional risk factors have previously been associated
with CAC progression in all persons, no matter
the risk level (15,19,29 –32). However, to our
knowledge, prediction of CAC progression using
novel marker combinations has not previously
been investigated, particularly in low-risk indi-
viduals. In addition, no studies have examined
traditional risk factors in the prediction of CAC
progression in low-risk persons.
Previous studies have shown that biomarkers do
not substantially improve the prediction of CHD/
CVD events beyond traditional risk factors (33–36).
It is therefore not surprising that our study revealed
that biomarkers do not predict CAC progression
beyond traditional risk factors because these risk
factors seem to create the inflammatory environ-
ment that generates changes in biomarker levels
responsible for CAC progression. Cardiovascular
risk factors, particularly those related to the meta-
bolic syndrome (obesity, dyslipidemia, hyperten-
sion, and insulin resistance), as well as diabetes and
smoking, lead to vascular injury with endothelial
damage, oxidized lipid accumulation, and inflam-
mation (24,37–39), which promote formation of
atherosclerotic plaque (37,39,40). This process is
considerably amplified by interactions between 1
risk factor (39). Calcification, which represents an
advanced stage of atherosclerosis/plaque formation,
is formed and regulated by this inflammatory milieu
and is an active process, similar to bone formation,
in which pericyte-like cells secrete a matrix scaffold
that later becomes calcified (39). Progression of
calcification likely represents the same process in a
vessel with persistent inflammation and continued
calcium formation. This inflammatory process is
responsible for formation of inflammatory, throm-
botic and endothelial dysfunction biomarkers and
creates a vicious cycle leading to further atheroscle-
rosis, which further worsens inflammation. As such,
biomarkers should be considered risk markers (as
they are termed) rather than risk factors, and efforts
aimed at risk factor modification in low-risk indi-Figure 2.
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151that have been established as independent predic-
tors of disease.
Other ﬁndings. Concordant with our main study
esults from developed models, the backward step-
ise selection process chose traditional risk factors
s being the most predictive of CAC progression in
hese already low-risk participants, even when inci-
ent and increased CAC were examined separately.
t is noteworthy that there were minimal differences
n associations of novel markers with incident versus
ncreased CAC. However, the predictive utility of
raditional risk factors for CAC progression was
etter for both groups combined.
Similar to other studies (20,30,41), our study
ound that compared with traditional risk factors
nd novel markers, baseline CAC score (for those
ith baseline CAC 0) was the single most
mportant predictor of CAC progression in low-
isk persons, with an increment of 0.03 in the
statistic analysis. This finding suggests that if
nitially assessed, those low-risk persons with
igher baseline CAC scores might benefit from
uture repeat testing for CAC progression, par-
icularly in a setting in which traditional risk
actors do not provide clear directives for risk
Figure 3. Calibration of Base Plus Novel Marker Best-Fit Models
The models were assessed in their abilities to predict individual risk
progression in the study population with model-estimated probabi
other abbreviations as in Figure 2.actor modification approaches, assuming that dem-nstration of CAC progression would change clin-
cal decision-making.
CIMT—another subclinical measure of vascular
isease, either singly, or in combination with bio-
arkers—did not improve the prediction of CAC
rogression beyond traditional risk factors. This
nding is particularly noteworthy because even
hough CIMT is a noninvasive test, its measure-
ent is dependent on technician and reader skills,
nd it is more costly than traditional risk factors
lus/minus biomarkers.
It is noteworthy that the risk of cancer associated
ith radiation exposure from cardiac CT is a
rojected risk which is low on an individual level
ut becomes significant while screening at the
opulation level. To this end, our study makes the
rgument for avoiding radiation from cardiac CT,
ut rather using traditional risk factors in screening
or atherosclerosis development and progression,
ven in low-risk persons.
Study limitations. First, our results might have
been different had we included other markers
associated with CHD/CVD such as troponin I or
B-type natriuretic peptide. However, these were
not available within the MESA cohort at the
CAC Progression
babilities by comparing observed coronary artery calcium (CAC)
of CAC progression. CRP  C-reactive protein; RF  risk factors;for
pro
litiestime of the current study. Second, because of the
L
M
U
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152age range and selection criteria for FRS 10%,
we were unable to stratify our findings according
to age, race/ethnicity, or sex due to small sample
size and limited power to make meaningful con-
clusions. Third, because there were few events in
these low-risk participants in the MESA cohort
after the second ascertainment of CAC (29 CHD
events or 1.1% of our study sample), we were
unable to compare prediction of clinical events
between our various models. Finally, sICAM
levels were imputed from sICAM measured in
only one-third of study participants.
It should be noted that follow-up CAC mea-
surements were obtained at a mean of 2.5 years
after the baseline study. As such, our study only
examines factors that predict CAC progression in
low-risk participants in the short term. A study
assessing longer-term CAC progression would be
useful.
C O N C L U S I O N S
Traditional cardiovascular risk factors seem to playFrom vulnerable plaque to vulnerable
1
2006;98:2H–15H.calibration, in the prediction of CAC progression in
those at low 10-year CHD risk according to FRS.
Individual or combinations of novel markers (in-
cluding CIMT and CRP) only minimally improved
this prediction when added to the model. Conse-
quently, for FRS-predicted low-risk persons, efforts
aimed at identifying those at risk for disease devel-
opment and progression should be focused on these
well-known traditional risk factors, rather than the
novel markers assessed here. This finding represents
an economical and effective method for CHD risk
screening and management decisions in low-risk
persons and could help avoid radiation risks, possi-
bly increased costs, and discovery of incidental
findings (42) (necessitating follow-up CT scans)
associated with CAC measurement in lower-risk
individuals.
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